Drug Information

Drug General Information
Drug ID
D0T8HR
Former ID
DNCL002468
Drug Name
Naptumomab estafenatox
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 2/3 [521947]
Company
Active Biotech
CAS Number
CAS 676258-98-3
Target and Pathway
Target(s) 5T4 ONCOFETAL antigen Target Info Immunomodulator [532633]
References
Ref 521947ClinicalTrials.gov (NCT00420888) ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma. U.S. National Institutes of Health.
Ref 532633Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.